Canadian policymakers must act to bolster the country’s local production base for off-patent drugs, after learning “difficult lessons” from the coronavirus pandemic, according to Jim Keon, president of the Canadian Generic Pharmaceutical Association.
Insisting in a blogpost hosted by Canada’s Apotex that the COVID-19 crisis had brought into “sharp focus” the value of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?